论文部分内容阅读
将光学异构消旋体引入人体,则其对映异构体(enantiomer,ENTM)均由体内的手性受体、酶及蛋白以二个完全不同的分子处理。这一性质被用于对映异构体的拆分(如以血浆蛋白,AGP等为拆分剂),更引起人们重视对映异构药物在体内代谢、分布和药理作用的差异。研究与临床实践表明,不仅其治疗效果不同(如熟知的DL-(±)合霉素仅为D(—)氯霉素的一半;普萘洛尔(propranolol)ι-异构体的药理
When an optical isomer is introduced into a human body, its enantiomer (ENTM) is treated with two completely different molecules by chiral receptors, enzymes and proteins in the body. This property has been used for enantiomeric resolution (such as plasma protein, AGP, etc. as a resolving agent), more attention has been given to the differences in the metabolism, distribution and pharmacological effects of enantiomeric drugs in vivo. Research and clinical practice have shown that not only are their therapeutic effects different (eg, well-known DL- (±) -cycline is only half of D (-) chloramphenicol; pharmacology of propranolol ι-isomer